CD94 Antibody (YA4704)
(Synonyms: KLRD1; CD94; Natural killer cells antigen CD94; KP43; Killer cell lectin-like receptor subfamily D member 1; NK cell receptor; CD antigen CD94; CD94 nanobody; )Based on 1 Customer Validation
CD94 Antibody (YA4704) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD94.
-
Host:
Mouse
-
Isotype:
IgG1
-
Application:
ELISA, FC
-
Reactivity :
Human
-
Formulation:
Supplied in PBS (pH7.4) containing 1% BSA and 0.2% Proclin950.
-
Conjugation:
Non-conjugated
Applications
| Application |
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
FC
FC: Flow Cytometry
|
|---|---|---|
| Dilution Ratio | 1:5000-100000 | 1-2μg/Test |
Product Details
CD94 Antibody (YA4704) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD94.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Calculated Molecular Weight Predicted band size: 21 kDa
Purified recombinant Human CD94 aa 32-179 (Extracellular).
Endogenous
affinity purified.
Non-conjugated
Unmodified
IgG1
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS (pH7.4) containing 1% BSA and 0.2% Proclin950.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
CD94 is an Immune receptor involved in self-nonself discrimination. In complex with KLRC1 or KLRC2 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia and non-classical MHC class Ib molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self. Primarily functions as a ligand binding subunit as it lacks the capacity to signal; KLRD1-KLRC1 acts as an immune inhibitory receptor. Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions. Dominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity. On intraepithelial CD8-positive gamma-delta regulatory T cells triggers TGFB1 secretion, which in turn limits the cytotoxic programming of intraepithelial CD8-positive alpha-beta T cells, distinguishing harmless from pathogenic antigens. In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell exhaustion. Upon HLA-E-peptide binding, transmits intracellular signals through KLRC1 immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHIP-1 and INPPL1/SHIP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules; KLRD1-KLRC2 acts as an immune activating receptor. On cytotoxic lymphocyte subsets recognizes HLA-E loaded with signal sequence-derived peptides from non-classical MHC class Ib HLA-G molecules, likely playing a role in the generation and effector functions of adaptive NK cells and in maternal-fetal tolerance during pregnancy. Regulates the effector functions of terminally differentiated cytotoxic lymphocyte subsets, and in particular may play a role in adaptive NK cell response to viral infection. Upon HLA-E-peptide binding, transmits intracellular signals via the adapter protein TYROBP/DAP12, triggering the phosphorylation of proximal signaling molecules and cell activation; (Microbial infection) Viruses like human cytomegalovirus have evolved an escape mechanism whereby virus-induced down-regulation of host MHC class I molecules is coupled to the binding of viral peptides to HLA-E, restoring HLA-E expression and inducing HLA-E-dependent NK cell immune tolerance to infected cells. Recognizes HLA-E in complex with human cytomegalovirus UL40-derived peptide (VMAPRTLIL) and inhibits NK cell cytotoxicity; (Microbial infection) May recognize HLA-E in complex with HIV-1 gag/Capsid protein p24-derived peptide (AISPRTLNA) on infected cells and may inhibit NK cell cytotoxicity, a mechanism that allows HIV-1 to escape immune recognition; (Microbial infection) Upon SARS-CoV-2 infection, may contribute to functional exhaustion of cytotoxic NK cells and CD8-positive T cells. On NK cells, may recognize HLA-E in complex with SARS-CoV-2 S/Spike protein S1-derived peptide (LQPRTFLL) expressed on the surface of lung epithelial cells, inducing NK cell exhaustion and dampening antiviral immune surveillance[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18].
-
Subcellular Localization
Cell membrane; Single-pass type II membrane protein
-
Expression
Tissue_specificity:Expression at protein levels in NK cell subsets (PubMed:21825173, PubMed:9430220, PubMed:9485206) . Expression at protein levels in memory/effect CD8-positive αβ T cell subsets (PubMed:12387742, PubMed:20952657) . Expression at protein levels in melanoma-specific cytotoxic T cell clones (PubMed:9485206) . Expression at protein levels in terminally differentiated cytotoxic γδ T cells (PubMed:20952657) . KLRD1-KLRC1 and KLRD1-KLRC2 are differentially expressed in NK cell and T cell populations, with only a few subsets simultaneously expressing both receptor complexes (PubMed:20952657) . -
Isoforms & Post-Translational Modification
Q13241 has 3 isomers: Q13241-1: 20513 Da (predicted); Q13241-2: 20641 Da (predicted); Q13241-3: 17109 Da (predicted).
-
Subunit
Can form disulfide-bonded heterodimer with NKG2 family members KLRC1 and KLRC2 (PubMed:18083576, PubMed:18332182, PubMed:18448674, PubMed:9655483). KLRD1-KLRC1 heterodimer interacts with peptide-bound HLA-E-B2M heterotrimeric complex. KLRD1 plays a prominent role in directly interacting with HLA-E (PubMed:18083576). KLRD1-KLRC1 interacts with much higher affinity with peptide-bound HLA-E-B2M than KLRD1-KLRC2 (PubMed:10428963, PubMed:9486650). Interacts with the adapter protein TYROBP/DAP12; this interaction is required for cell surface expression and cell activation (PubMed:15940674, PubMed:9655483)
-
SwissProt ID
-
Synonyms
KLRD1; CD94; Natural killer cells antigen CD94; KP43; Killer cell lectin-like receptor subfamily D member 1; NK cell receptor; CD antigen CD94; CD94 nanobody;
Documentation
References
[1]. Boyington JC, et al. Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. Immunity. 1999 Jan;10(1):75-82. [Content Brief]
[2]. Bhagat G, et al. Small intestinal CD8+TCRgammadelta+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. J Clin Invest. 2008 Jan;118(1):281-93. [Content Brief]
[3]. Sullivan LC, et al. The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity. 2007 Dec;27(6):900-11. [Content Brief]
[5]. Braud VM, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998 Feb 19;391(6669):795-9. [Content Brief]
[6]. Llano M, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol. 1998 Sep;28(9):2854-63. [Content Brief]
[7]. Jabri B, et al. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity. 2002 Oct;17(4):487-99. [Content Brief]
[8]. Valiante NM, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997 Dec;7(6):739-51. [Content Brief]
[9]. Kamiya T, et al. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest. 2019 May 1;129(5):2094-2106. [Content Brief]
[10]. Le Dréan E, et al. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol. 1998 Jan;28(1):264-76. [Content Brief]
[11]. André P, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018 Dec 13;175(7):1731-1743.e13. [Content Brief]
[12]. Kabat J, et al. Role that each NKG2A immunoreceptor tyrosine-based inhibitory motif plays in mediating the human CD94/NKG2A inhibitory signal. J Immunol. 2002 Aug 15;169(4):1948-58. [Content Brief]
[13]. Gumá M, et al. The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells. Eur J Immunol. 2005 Jul;35(7):2071-80. [Content Brief]
[14]. Lanier LL, et al. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity. 1998 Jun;8(6):693-701. [Content Brief]
[15]. Rölle A, et al. Distinct HLA-E Peptide Complexes Modify Antibody-Driven Effector Functions of Adaptive NK Cells. Cell Rep. 2018 Aug 21;24(8):1967-1976.e4. [Content Brief]
[16]. Angelini DF, et al. NKG2A inhibits NKG2C effector functions of γδ T cells: implications in health and disease. J Leukoc Biol. 2011 Jan;89(1):75-84. [Content Brief]
[17]. Lopez-Vergès S, et al. Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14725-32. [Content Brief]
[18]. Bortolotti D, et al. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway. Cells. 2020 Aug 26;9(9):. [Content Brief]